1.56
-0.01(-0.64%)
Currency In USD
| Previous Close | 1.57 |
| Open | 1.55 |
| Day High | 1.7 |
| Day Low | 1.5 |
| 52-Week High | 5.33 |
| 52-Week Low | 0.89 |
| Volume | 148,238 |
| Average Volume | 314,528 |
| Market Cap | 41.38M |
| PE | -1.46 |
| EPS | -1.07 |
| Moving Average 50 Days | 2.06 |
| Moving Average 200 Days | 2.14 |
| Change | -0.01 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $127.87 as of December 21, 2024 at a share price of $1.56. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 2 years ago, it would be worth $528.81 as of December 21, 2024 at a share price of $1.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics To Present At Biotech Showcase 2025
GlobeNewswire Inc.
Dec 11, 2024 1:30 PM GMT
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery PlatformBETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company lead
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
GlobeNewswire Inc.
Oct 23, 2024 12:00 PM GMT
GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology Compared to Traditional Kinase Inhibitors B
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 15, 2024 11:00 AM GMT
BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the